Evotec Announces Research Collaboration With C4X - Quick Facts

(RTTNews) - Evotec AG (EVTCY.PK, EVOTF.PK) announced a research collaboration with C4X Discovery Holdings plc to optimise Orexin-1 selective inhibitors discovered through C4XD's NMR technology. Evotec will apply its drug discovery platform with C4XD to further develop several series of Orexin-1 selective inhibitors.

"C4XD has an exciting technology that can really revolutionise how rational drug design is conducted, particularly on targets like Orexin where the conformation of drug-like ligands is particular important to on-target potency. With Evotec's complementary expertise in computational chemistry, medicinal chemistry and pharmacology we look forward to help drive C4XD's objective to develop compounds to treat addictive disorders," said Mario Polywka, COO of Evotec.

C4XD is a Manchester-based company, which was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates.